Healthcare Industry News: Bausch Health Companies
News Release - October 24, 2018
Bausch & Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite(TM) Vision Enhancement System On IBM CloudWatson IoT Services on the IBM Cloud Are Being used by Bausch & Lomb to Help Eye Surgeons Increase Efficiency, Cut Costs and Improve Workflow when using Stellaris Elite™ Vision Enhancement System
LAVAL, Quebec and ARMONK, N.Y., Oct. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a global eye health company and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE: /TSX: BHC), and IBM (NYSE: IBM) today announced the new eyeTELLIGENCE™ applications which will run on the IBM Cloud to help eye surgeons and surgical facilities work more efficiently using Stellaris Elite™ vision enhancement systems. The companies built the eyeTELLIGENCE applications to deliver surgeons first-in-class efficiency features that include expedited technical support and the ability to synchronize preferred surgical settings across multiple Stellaris Elite systems.
Stellaris Elite systems are continuously monitored and maintained by Bausch & Lomb to ensure surgeons experience its highest levels of performance. Using Watson Internet of Things (IoT) services on the IBM Cloud, Bausch & Lomb will have a centralized view of operational and performance data from its Stellaris Elite systems around the United States. This allows Bausch & Lomb to pinpoint and respond to technical and service requests made by surgeons and staff promptly, as well as identify system conditions that can be addressed proactively to limit or minimize down-time.
"Similar to what is being seen across the entire healthcare spectrum, ophthalmologists are under increasing pressure to find ways to work more efficiently," said Tracy Valorie, senior vice president and general manager, U.S. Surgical and Pharmaceuticals, Bausch & Lomb. "With the data management capabilities of IBM Cloud coupled with the Stellaris Elite system and the clinical expertise of Bausch & Lomb, these new applications will help to enhance surgeons' ability to increase efficiency, reduce programming steps when moving from one surgical center to the next and increase the consistency of their system management."
By using the new eyeTELLIGENCE apps on the Stellaris Elite user interface, surgeons can gather information about the system and make service requests or report technical issues, which are then sent via the IBM Cloud to the appropriate team at Bausch & Lomb. Surgeons can also grant Bausch & Lomb remote access into their Stellaris Elite system through the IBM Cloud, so that service teams can make technical assessments and software updates expeditiously.
The eyeTELLIGENCE application also allows surgeons to sync their settings across all of the Stellaris Elite machines on which they operate, no matter the location. Surgeons need only login to their account from one machine to access and adjust settings. If a setting adjustment is made and saved on that machine, those changes can be applied to all Stellaris Elite machines connected to their account.
"Our work with Bausch & Lomb is tailored to deliver the benefits they wanted most from the cloud, in conjunction with the security and compliance that their surgical systems require," said John Granger, general manager, GBS Cloud Application Innovation, IBM. "The security, flexibility and speed of the IBM Cloud positions it as the ideal platform to run the eyeTELLIGENCE network."
The eyeTELLIGENCE applications are the result of IBM's collaboration with Bausch & Lomb to design a cloud strategy tailored to the needs of their customers. The foundation of the IBM Cloud provides Bausch & Lomb and its customers with high levels of inherent security within its architecture, as well as the ability to control where data streaming in from its systems resides in IBM's global data center network.
About Stellaris Elite
Introduced in 2017, the Stellaris Elite vision enhancement system is Bausch & Lomb's next-generation surgical platform, which offers cataract and retina capabilities in a single platform, as well as many cutting-edge innovations. These include:
- the Adaptive Fluidics™ chamber stabilization system, which combines precise aspiration control with predictive infusion management to create a highly responsive and controlled surgical environment;
- the Attune® energy management system, which utilizes highly efficient emulsification to complement Adaptive Fluidics and deliver effective, low energy, controlled lens removal;
- a variety of vitrectomy cutters operating up to an effective cut rate of 15,000 cuts per minute (cpm), and
- a comprehensive portfolio of high-performance laser probes.
About IBM Cloud
With $18.5B in annual cloud revenue, IBM is the global leader in enterprise cloud with a platform designed to meet the evolving needs of business and society. Moving past productivity and cost improvements, the IBM Cloud is tuned for the AI and data demands that are driving true differentiation in today's enterprise. IBM's private, public and hybrid offerings provide the global scale businesses need to support innovation across industries, while its nearly 60 Cloud Data Centers across 19 countries help clients meet their expanding data locality requirements. For more information on IBM Cloud, visit: ibm.com/cloud.
About Bausch & Lomb
Bausch & Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, and ophthalmic surgical devices and instruments. Bausch & Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
All other product/brand names are trademarks of the respective owners.
© 2018 Bausch & Lomb Incorporated.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch & Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE(TM) Clinical Decision Support Software
Bausch & Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device